This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haverstick, D. M. Articles by Gray, L. S. Search for Related Content PubMed PubMed Citation Articles by Haverstick, D. M. Articles by Gray, L. S.

Inhibition of Human Prostate Cancer Proliferation in Vitro and in a Mouse Model by a Compound Synthesized to Block Ca²⁺ Entry¹

Departments of Pathology [D. M. H., L. S. G.] and Chemistry [T. N. H., T. L. M.], University of Virginia, Charlottesville, Virginia 22908

Accelerated Ca²⁺ entry may be one component of the pathway regulating the proliferative phenotype of some types of cancer. Thus, a pharmacological agent with the ability to retard Ca²⁺ influx in susceptible cancers might inhibit proliferation of them by a cytostatic mechanism rather than by inducing cytotoxicity. We have developed a chemical synthetic scheme that has produced a small library of novel compounds that block Ca²⁺ entry induced by occupancy of the P2 receptor in two prostate cancer cell lines and inhibit proliferation of these cells in vitro. One of the agents, named TH-1177, was used to treat severe combined immunodeficient mice inoculated with the human prostate cancer line PC-3. Although the doses used and treatment schedule were chosen arbitrarily, treatment extended the mean life span of mice bearing tumors by up to 38%. Treatment of mice without cancer at doses 18 times that used in mice with tumors was not associated with any obvious toxicity, either grossly or on histological examination. These results suggest that novel cytostatic agents with efficacy against human prostate cancer cells can be developed by chemical synthesis of agents directed at the Ca²⁺ entry pathway.

This article has been cited by other articles:

				S. B. Semenova, I. O. Vassilieva, A. F. Fomina, A. L. Runov, and Y. A. Negulyaev Endogenous expression of TRPV5 and TRPV6 calcium channels in human leukemia K562 cells Am J Physiol Cell Physiol, May 1, 2009; 296(5): C1098 - C1104. [Abstract] [Full Text] [PDF]

				K. A. Bolanz, M. A. Hediger, and C. P. Landowski The role of TRPV6 in breast carcinogenesis Mol. Cancer Ther., February 1, 2008; 7(2): 271 - 279. [Abstract] [Full Text] [PDF]

				O. Mignen, C. Brink, A. Enfissi, A. Nadkarni, T. J. Shuttleworth, D. R. Giovannucci, and T. Capiod Carboxyamidotriazole-induced inhibition of mitochondrial calcium import blocks capacitative calcium entry and cell proliferation in HEK-293 cells J. Cell Sci., December 1, 2005; 118(23): 5615 - 5623. [Abstract] [Full Text] [PDF]

				W. J. Lee, J. A. Robinson, N. A. Holman, M. N. McCall, S. J. Roberts-Thomson, and G. R. Monteith Antisense-mediated Inhibition of the Plasma Membrane Calcium-ATPase Suppresses Proliferation of MCF-7 Cells J. Biol. Chem., July 22, 2005; 280(29): 27076 - 27084. [Abstract] [Full Text] [PDF]

				A. Apati, J. Janossy, A. Brozik, P. I. Bauer, and M. Magocsi Calcium Induces Cell Survival and Proliferation through the Activation of the MAPK Pathway in a Human Hormone-dependent Leukemia Cell Line, TF-1 J. Biol. Chem., March 7, 2003; 278(11): 9235 - 9243. [Abstract] [Full Text] [PDF]

				C. A. Gilchrist, M. Leo, C. G. Line, B. J. Mann, and W. A. Petri Jr. Calcium Modulates Promoter Occupancy by the Entamoeba histolytica Ca2+-binding Transcription Factor URE3-BP J. Biol. Chem., February 7, 2003; 278(7): 4646 - 4653. [Abstract] [Full Text] [PDF]